This protocol addresses leukemia cutis arising in the context of acute myeloid leukemia — a presentation in which leukemic cells infiltrate the skin concurrent with, or as a manifestation of, underlying AML.
Acute myeloid leukemia is the second most common leukemia in adults. In this setting, management of the underlying AML drives the treatment approach for leukemia cutis — cutaneous involvement does not alter the primary systemic strategy.
Systemic induction chemotherapy is the cornerstone of management, with the choice of regimen shaped by patient fitness and molecular tumour profile — including whether additional targeted therapy is appropriate. Dosing, full eligibility criteria, and the complete algorithm are available in the structured protocol.
DOI: 10.3390/cancers15225393